.
.
.
Exhibit 99.8
CONTACTS:
LORUS THERAPEUTICS INC. CANADIAN MEDIA CONTACT: US MEDIA CONTACT
Corporate Communications Eliza Walsh Jennifer Taylor
Grace Tse Mansfield Communications Inc. Mansfield Communications Inc.
Tel: (416) 798-1200 ext. 380 Tel: (416) 599-0024 Tel: (212) 370-5045
Email: ir@lorusthera.com Email: eliza@mcipr.com Email: jennifer@mcipr.com
LORUS ANNOUNCES AMERICAN STOCK EXCHANGE LISTING
TSX: LOR
OTC BB: LORFF
TORONTO - FEBRUARY 18, 2004 - Lorus Therapeutics Inc. ("Lorus") today announced
that it has been approved for trading on the American Stock Exchange under the
symbol "LRP," subject to the fulfillment of certain conditions. Trading is
expected to commence on Monday, February 23, 2004.
"This new listing in the United States will increase our visibility and
facilitate the broader participation of American investors in Lorus," said Dr.
Jim Wright, CEO of Lorus.
About Lorus
Lorus is a biopharmaceutical company focused on the research and development of
cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical,
clinical and regulatory expertise by developing new drug candidates that can be
used, either alone, or in combination, to successfully manage cancer. Through
its own discovery efforts and an acquisition and in-licensing program, Lorus is
building a portfolio of promising anticancer drugs. Late-stage clinical
developments and marketing may be done in cooperation with strategic
pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public
company listed on the Toronto Stock Exchange under the symbol LOR, and on the
OTC BB exchange under the symbol LORFF.
Forward Looking Statements
Except for historical information, this press release contains forward-looking
statements, which reflect the Company's current expectation and assumptions, and
are subject to a number of risks and uncertainties that could cause actual
results to differ materially from those anticipated. These forward-looking
statements involve risks and uncertainties, including, but not limited to,
changing market conditions, the Company's ability to obtain patent protection
and protect its intellectual property rights, commercialization limitations
imposed by intellectual property rights owned or controlled by third parties,
intellectual property liability rights and liability claims asserted against the
Company, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, product development delays, the Company's ability to attract
and retain business partners and key personnel, future levels of government
funding, the Company's ability to obtain the capital required for research,
operations and marketing and other risks detailed from time-to-time in the
Company's ongoing quarterly filings, annual information form, annual reports and
20-F filings. We undertake no obligation to publicly update or revise any
forward looking statements, whether as a result of new information, future
events or otherwise.
Lorus Therapeutics Inc.'s press releases are available through the Company's
Internet site: http://www.lorusthera.com.
About American Stock Exchange
The American Stock Exchange(R) (Amex(R)) is the only primary exchange that
offers trading across a full range of equities, options and exchange traded
funds (ETFs), including structured products and HOLDRSSM. In addition to its
role as a national equities market, the Amex is the pioneer of the ETF,
responsible for bringing the first domestic product to market in 1993. Leading
the industry in ETF listings, the Amex lists 124 ETFs to date. The Amex is also
one of the largest options exchanges in the U.S., trading options on broad-based
and sector indexes as well as domestic and foreign stocks.
-30-